1. Home
  2. DCOM vs GLUE Comparison

DCOM vs GLUE Comparison

Compare DCOM & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dime Community Bancshares Inc.

DCOM

Dime Community Bancshares Inc.

HOLD

Current Price

$33.84

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$20.49

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCOM
GLUE
Founded
1864
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
DCOM
GLUE
Price
$33.84
$20.49
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$36.40
$29.50
AVG Volume (30 Days)
340.3K
2.7M
Earning Date
01-21-2026
03-19-2026
Dividend Yield
2.94%
N/A
EPS Growth
329.09
N/A
EPS
2.36
0.25
Revenue
$409,901,000.00
$181,538,000.00
Revenue This Year
$21.40
$84.02
Revenue Next Year
$12.62
N/A
P/E Ratio
$14.42
$81.29
Revenue Growth
47.45
1112.27
52 Week Low
$23.25
$3.50
52 Week High
$34.86
$25.77

Technical Indicators

Market Signals
Indicator
DCOM
GLUE
Relative Strength Index (RSI) 67.76 48.60
Support Level $32.51 $22.05
Resistance Level $34.86 $23.29
Average True Range (ATR) 1.16 1.30
MACD 0.26 -0.53
Stochastic Oscillator 81.70 12.32

Price Performance

Historical Comparison
DCOM
GLUE

About DCOM Dime Community Bancshares Inc.

Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: